The EMANATE (NCT05093634) trial is a multicenter, phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of setmelanotide in individuals aged 6 to 65 years with obesity due to rare heterozygous variants in genes involved in the melanocortin-4 receptor (MC4R) pathway. This evidence concerns the gene MC4R and obesity due to melanocortin 4 receptor deficiency.